Australia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.70-1.80 (-5.54%)
At close: 04:00PM EST
31.19 +0.49 (+1.60%)
After hours: 07:56PM EST
Full screen
Loading interactive chart…
  • Motley Fool

    Why ChemoCentryx Stock Tanked in 2021

    Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

  • Simply Wall St.

    When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Breakeven?

    ChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to...

  • GlobeNewswire

    ChemoCentryx to Present at Two Upcoming Investor Conferences

    SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare ConferenceWednesday, January 12 at 4:30 p.m. Eastern Time H.C. Wainwright Virtual BioConnect ConferenceOn-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time A live audio webcast of the J.P. Morgan presenta